|
Market Closed -
Nasdaq
21:00:00 22/10/2026 BST
|
5-day change | 1st Jan Change | ||
| 63.04 USD | +0.67% |
|
+3.36% | -17.01% |
| 10-15 | UBS Adjusts Price Target on PTC Therapeutics to $90 From $80, Maintains Buy Rating | MT |
| 10-08 | RBC Cuts Price Target on PTC Therapeutics to $75 From $85, Keeps Sector Perform Rating | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Compared values
| Sector | Change | 5-day change | YTD change | 1-year change | 5-year change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| PTC THERAPEUTICS, INC. | Other Pharmaceuticals | +0.67% | +3.36% | -17.01% | -5.23% | +75.16% | 5.23B |  | | |
- Stock Market
- Stocks
- PTCT Stock
- Charts PTC Therapeutics, Inc.
- Comparison Chart
Select your edition
All financial news and data tailored to specific country editions
